SirTLab Corporation
SEVERE LIVER DISEASE&LONGEVITY
ABOUT
SirTLab is the leader in Restoring SIRT6 Expression for Severe Liver Diseases and Diseases of Aging
•Sirtuin 6 (SIRT6) is a Key Regulator for Health in All Cells.
•Levels of SIRT6 are reduced in liver diseases: NASH1, other cirrhosis, metabolic syndrome, acetaminophen toxicity.
•SIRTLab patented SIRT6-mRNA-LNP2 for liver specific expression of SIRT6 based on >18 years of research.
•First in Human expected in 2H 2023
•Potential for truly disease modifying therapy for a variety of severe liver disorders
1NASH non-alcoholic steatohepatitis
2LNP lipid nanoparticle
SirTLab Corporation ©2022 | Confidential and Proprietary
Livers from Mice with NAFL1 (Stage 2 / 3 – Fatty, Early Fibrotic)
CONTROL Treatment
SIRT6 mRNA-LNP IV BIW x 3 wks
Fatty, Fibrotic Liver
Restored Normal Liver
SIRT6 mRNA for:
·Non-Alcoholic Fatty Liver (NAFL):
·Focus on NASH Stages 3 & 4
·Aging and Frailty
·Liver cirrhosis (viral, alcoholic)
·Type II diabetes
·Hyperlipidemia
·Obesity
·Neurodegenerative Diseases
·Liver cancer (HCC)
Data on File, SIRTLab Corporation (2 days after last dose)
1NAFL non-alcoholic fatty liver
2BIW twice per week